Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
This is the sixth successful USFDA audit for this facility
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Govt announces vaccination programme for kids and those above 60 years of age
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Subscribe To Our Newsletter & Stay Updated
